Corcept Forecasts 36.3% Q4 Revenue Gain After $207.6M Quarter Miss
Corcept reported $207.6M in its most recent quarter, up 13.7% year-on-year, missing analyst revenue estimates and full-year guidance. Analysts forecast 36.3% revenue growth for Q4 versus 34.3% a year ago, lagging peers—Eli Lilly’s 42.6% and Bristol-Myers’ 1.4% gains.
1. Recent Quarter Performance
Corcept posted $207.6M in revenue in its most recent quarter, a 13.7% year-on-year increase that still fell short of analyst consensus. Full-year guidance was reduced below expectations, highlighting softer performance trends.
2. Q4 Revenue Expectations
Analysts project 36.3% revenue growth for Q4, up from 34.3% in the same period last year. Coverage levels have been stable over 30 days despite repeated revenue estimate misses over two years.
3. Peer Performance Comparison
Peers in branded pharmaceuticals outperformed Corcept: Eli Lilly achieved 42.6% revenue growth, exceeding estimates by 7.4%, while Bristol-Myers Squibb grew 1.4%, topping forecasts by 4.8%. Corcept’s shares declined about 23% over the past month, trailing the segment average.
4. Analyst Price Targets
The average analyst price target stands at $76.40, suggesting substantial upside potential if Corcept can align upcoming results with industry leaders. Investors will watch for guidance and execution to gauge reacceleration prospects.